Clinical Trials Browser

Phase 1/2 × Glioma × Panitumumab × Clear all

NCT03510208 2026-02-09

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Phase 1/2 Recruiting

Brain Neoplasms, Glioma